by Raynovich Rod | Jan 12, 2017 | Biopharmaceuticals
Biotech Rally Snuffed Out Again By Tough Trump Talk on Drug Pricing Any market optimism from the Conference about new product pipelines, M&A and “read-outs” on clinical data was chilled by Trump’s idea to let Medicare negotiate for better drug...
by Raynovich Rod | Jan 10, 2017 | Biopharmaceuticals, Clinical Diagnostics and Tools
Wet Stormy Weather in San Francisco-A New Indicator for a Good Year Ahead? About 8000+ investors, entrepreneurs and life science Company executives piled into the Westin St. Francis for the Annual J.P.Morgan Healthcare Conference and maybe 10k+ others at several other...
by Raynovich Rod | Jan 9, 2017 | Biopharmaceuticals
We will publish updates this week from the Conference. As of 3:45p EST the biotech sector is rallying. The IBB is up 1.6% and the XBI is up 3.5%. Biotech stocks were helped by the buyout of Ariad Pharmaceuticals (ARIA) by Takeda Pharmaceuticals in a deal worth $5.2B....
by Raynovich Rod | Jan 2, 2017 | Biopharmaceuticals
Update-2…1/6/17– Three Day Biotech Rally…12N EST NASDAQ at New Highs 5532 XBI is up 5 points since last Friday’s close to $63.45;The IBB is up 16 points to $280. Investors are betting on a turnaround in healthcare with positive news from the...
by Raynovich Rod | Dec 20, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Sector: What’s Going On With Dx and Tools Stocks? We dropped coverage of Life Science diagnostics and tools stocks in January 2016 just after the severe market correction began. Of course the downdraft opened up great values in several stocks.We...
by Raynovich Rod | Dec 19, 2016 | Biopharmaceuticals
Biotechs Fade After Promising Start-Smaller Cap Winners Biotech stocks got a jump-start this morning peaked quickly then abruptly sold off at about 2p. The IBB ended down 1.33% to 268.79 off recent five-day highs of $274 and considerably off post-election highs of...
by Raynovich Rod | Dec 12, 2016 | Biopharmaceuticals
Update-1 2:30P EST… Improved Tone in Selective Biotech Stocks Maybe it’s bottom fishing or the end of tax selling but today we can see buyers coming in for large cap biotechs. However the backdrop is still cautious because of drug pricing rhetoric and a...
by Raynovich Rod | Dec 8, 2016 | Biopharmaceuticals
Biotechs Unhinged-Roiled by Commentary and Tweet storms Biotech stocks rallied briefly early in the week but sold off abruptly over the past two days with a quote from Trump in a Time Person of the Year article as saying, “I’m going to bring down drug...
by Raynovich Rod | Nov 29, 2016 | Biopharmaceuticals
Market Reversal in Biotech Offers Bullish Set-Up After one of the worst down days in months yesterday biotech stocks broadly reversed today giving a short term “nibble” signal. The macro environment got support from economic data as well with upward Q3 GDP...
by Raynovich Rod | Nov 23, 2016 | Biopharmaceuticals
Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off. Both Biogen (BIIB) -aducanumab- and Lilly (LLY)- solanezumab -drugs in development are engineered antibodies that attack beta amyloid targets in the...